This systematic review examines the therapeutic potential of melanocortin receptor (MCR) agonists, such as melanotan I, melanotan II, and bremelanotide, in treating sexual dysfunction in both men and women. These agents act on central melanocortin pathways, differentiating them from traditional treatments like phosphodiesterase type 5 inhibitors. Clinical and preclinical studies
